Old drug with a new purpose may offer hope for children with neuroblastoma
Wednesday, April 14, 2010 - 11:28
in Health & Medicine
A new Phase I clinical trial sponsored by the Vermont Cancer Center at the University of Vermont and Fletcher Allen Health Care has opened to test the investigational drug DFMO, or alpha-difluoromethylornithine, as a treatment for the pediatric cancer neuroblastoma. According to researchers at the Cancer Research Center at the University of Hawaii, and the Vermont Cancer Center , the study will monitor the safety of DFMO usage among neuroblastoma patients and test whether the drug is effective in reducing or eradicating neuroblastoma tumor cells.